MedTrace Logo

A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®

NCT03259958 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2018-08-01

No results posted yet for this study

Summary

A study to assess the steady-state bioequivalence of once-weekly Corplex™ Donepezil 10 mg Transdermal Delivery System (TDS) compared to daily administration of Aricept®

Conditions

Interventions

DRUG

Donepezil TDS

Donepezil Hydrochloride Transdermal Delivery System

DRUG

Aricept

Aricept Tablet

Sponsors & Collaborators

  • Corium, Inc.

    lead INDUSTRY

Principal Investigators

  • Danielle Armas, MD · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-30
Primary Completion
2018-03-13
Completion
2018-03-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03259958 on ClinicalTrials.gov